Lil
03-23-2006, 08:24 AM
Business Editors
RENO, Nev.--(BUSINESS WIRE)--March 23, 2006--
Lifeline Biotechnologies, Inc. (Pink Sheets:LBTN)
announced today that the company is actively pursuing acquisition and
merger candidates to continue the steady growth of the Company.
"Lifeline Biotechnologies has incorporated a strategy to rapidly
develop the company through the mergers and acquisition of other
companies in the Medical, Nutraceutical, and Energy Industries. This
will enable the company to accumulate assets and increase revenues and
profitability," stated Jim Holmes, President and CEO of Lifeline
Biotechnologies, Inc.
Lifeline Biotechnologies recently announced that they have
completed the initial patient testing of their OvaScope(TM) product.
This micro endoscope has been designed by Lifeline Biotechnologies to
be used by physicians to assist in the early detection of ovarian
cancer.
About Lifeline Biotechnologies, Inc.
Lifeline Biotechnologies, Inc. is a company with innovative
medical technologies committed to the improvement of the quality of
life through exceptional health care systems. These technologies focus
on prevention, early detection, diagnosis and quick recovery of a
number of disease conditions. The company's Cancer Detection
technologies deal with cutting edge innovation to assist practicing
physicians in the delivery of quality medical care. The MastaScope(TM)
is used in the early detection of cancer and other abnormalities of
the breast. The MastaScope(TM) has completed development and has
entered the marketplace in the US and internationally. The First
Warning System(TM) for assisting in the early detection of breast
cancer and the OvaScope(TM) for assisting in the early detection of
ovarian cancer are continuing to be developed by the company. More
information is available at the company's website: www.lbtn.com.
Safe Harbor
This release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 27E
of the Securities Act of 1934. Statements contained in this release
that are not historical facts may be deemed to be forward-looking
statements. Investors are cautioned that forward-looking statements
are inherently uncertain. Actual performance and results may differ
materially from that projected or suggested herein due to certain
risks and uncertainties including, without limitation, ability to
obtain financing and regulatory and shareholder approval for
anticipated actions.
KEYWORD: NORTH AMERICA NEVADA UNITED STATES
INDUSTRY KEYWORD: WOMEN HEALTH BIOTECHNOLOGY CLINICAL TRIALS MEDICAL DEVICES ONCOLOGY RESEARCH & SCIENCE CONSUMER MERGER/ACQUISITION
SOURCE: Lifeline Biotechnologies, Inc.
CONTACT INFORMATION:
Big Apple Consulting USA, Inc.
(for Lifeline Biotechnologies, Inc.)
Investor Relations
Rodney Marvel, 407-884-0444 or 1-866-THE-APPLE
RENO, Nev.--(BUSINESS WIRE)--March 23, 2006--
Lifeline Biotechnologies, Inc. (Pink Sheets:LBTN)
announced today that the company is actively pursuing acquisition and
merger candidates to continue the steady growth of the Company.
"Lifeline Biotechnologies has incorporated a strategy to rapidly
develop the company through the mergers and acquisition of other
companies in the Medical, Nutraceutical, and Energy Industries. This
will enable the company to accumulate assets and increase revenues and
profitability," stated Jim Holmes, President and CEO of Lifeline
Biotechnologies, Inc.
Lifeline Biotechnologies recently announced that they have
completed the initial patient testing of their OvaScope(TM) product.
This micro endoscope has been designed by Lifeline Biotechnologies to
be used by physicians to assist in the early detection of ovarian
cancer.
About Lifeline Biotechnologies, Inc.
Lifeline Biotechnologies, Inc. is a company with innovative
medical technologies committed to the improvement of the quality of
life through exceptional health care systems. These technologies focus
on prevention, early detection, diagnosis and quick recovery of a
number of disease conditions. The company's Cancer Detection
technologies deal with cutting edge innovation to assist practicing
physicians in the delivery of quality medical care. The MastaScope(TM)
is used in the early detection of cancer and other abnormalities of
the breast. The MastaScope(TM) has completed development and has
entered the marketplace in the US and internationally. The First
Warning System(TM) for assisting in the early detection of breast
cancer and the OvaScope(TM) for assisting in the early detection of
ovarian cancer are continuing to be developed by the company. More
information is available at the company's website: www.lbtn.com.
Safe Harbor
This release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 27E
of the Securities Act of 1934. Statements contained in this release
that are not historical facts may be deemed to be forward-looking
statements. Investors are cautioned that forward-looking statements
are inherently uncertain. Actual performance and results may differ
materially from that projected or suggested herein due to certain
risks and uncertainties including, without limitation, ability to
obtain financing and regulatory and shareholder approval for
anticipated actions.
KEYWORD: NORTH AMERICA NEVADA UNITED STATES
INDUSTRY KEYWORD: WOMEN HEALTH BIOTECHNOLOGY CLINICAL TRIALS MEDICAL DEVICES ONCOLOGY RESEARCH & SCIENCE CONSUMER MERGER/ACQUISITION
SOURCE: Lifeline Biotechnologies, Inc.
CONTACT INFORMATION:
Big Apple Consulting USA, Inc.
(for Lifeline Biotechnologies, Inc.)
Investor Relations
Rodney Marvel, 407-884-0444 or 1-866-THE-APPLE